Use of the GARDEX™ Embolic Protection Device During Percutaneous Coronary Interventions of Saphenous Vein Graft
Phase I Study to Demonstrate the Safety and Performance of the GARDEX™ Embolic Protection Device When Used During Percutaneous Coronary Intervention (PCI) of Saphenous Vein Graft
Sponsor: Gardia Medical
Terminated
This trial was terminated. No reason was provided.
A NA clinical study on Embolism and Myocardial Ischemia, this trial is terminated or withdrawn. The trial is conducted by Gardia Medical and has accumulated 8 data snapshots since 2009. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Terminated NA
-
Sep 2024 — Sep 2025 [monthly]
Terminated NA
-
Jul 2024 — Sep 2024 [monthly]
Terminated NA
-
Jan 2021 — Jul 2024 [monthly]
Terminated NA
-
Jun 2018 — Jan 2021 [monthly]
Terminated NA
▶ Show 3 earlier versions
-
Jan 2018 — Jun 2018 [monthly]
Terminated NA
Phase: PHASE1 → NA
-
Feb 2017 — Jan 2018 [monthly]
Terminated PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE1
First recorded
Dec 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Gardia Medical
For direct contact, visit the study record on ClinicalTrials.gov .